Apixaban versus Warfarin in Atrial Fibrillation REPLY
Publication
, Journal Article
Granger, CB; Hanna, M; Wallentin, L
Published in: NEW ENGLAND JOURNAL OF MEDICINE
January 5, 2012
Duke Scholars
Published In
NEW ENGLAND JOURNAL OF MEDICINE
ISSN
0028-4793
Publication Date
January 5, 2012
Volume
366
Issue
1
Start / End Page
89 / 89
Publisher
MASSACHUSETTS MEDICAL SOC
Related Subject Headings
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Granger, C. B., Hanna, M., & Wallentin, L. (2012). Apixaban versus Warfarin in Atrial Fibrillation REPLY. NEW ENGLAND JOURNAL OF MEDICINE, 366(1), 89–89.
Granger, Christopher B., Michael Hanna, and Lars Wallentin. “Apixaban versus Warfarin in Atrial Fibrillation REPLY.” NEW ENGLAND JOURNAL OF MEDICINE 366, no. 1 (January 5, 2012): 89–89.
Granger CB, Hanna M, Wallentin L. Apixaban versus Warfarin in Atrial Fibrillation REPLY. NEW ENGLAND JOURNAL OF MEDICINE. 2012 Jan 5;366(1):89–89.
Granger, Christopher B., et al. “Apixaban versus Warfarin in Atrial Fibrillation REPLY.” NEW ENGLAND JOURNAL OF MEDICINE, vol. 366, no. 1, MASSACHUSETTS MEDICAL SOC, Jan. 2012, pp. 89–89.
Granger CB, Hanna M, Wallentin L. Apixaban versus Warfarin in Atrial Fibrillation REPLY. NEW ENGLAND JOURNAL OF MEDICINE. MASSACHUSETTS MEDICAL SOC; 2012 Jan 5;366(1):89–89.
Published In
NEW ENGLAND JOURNAL OF MEDICINE
ISSN
0028-4793
Publication Date
January 5, 2012
Volume
366
Issue
1
Start / End Page
89 / 89
Publisher
MASSACHUSETTS MEDICAL SOC
Related Subject Headings
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences